Kidney Cancer Trials

The purpose of this study is to assess the safety and effectiveness of the investigational drugs ALLO-647 (a type of immunotherapy) and ALLO-316 (a type of immunotherapy) in people with advanced clear cell renal cell (kidney) cancer. ALLO-647 is an antibody designed to target some kinds of white blood cells. It will be given in combination with a standard chemotherapy regimen (fludarabine and cyclophosphamide) to prepare patients to receive ALLO-316. ALLO-316 is made in a laboratory from white blood cells (T cells) collected from a healthy donor and is a form of cellular therapy. These cells are modified (“CAR T cells”) to help the immune system recognize and kill kidney cancer cells. ALLO-647 will help ALLO-316 work better by reducing the immune system’s ability to fight the modified T cells. Participants in this study will receive standard chemotherapy with or without ALLO-647, followed by ALLO-316. All medications are given intravenously (IV) in clinic. Dosing and dosing schedule will be provided by the treating physician.

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy, such as nivolumab (Opdivo) and ipilimumab (Yervoy), may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Targeted therapy, such as cabozantinib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known how well the combination of cabozantinib and nivolumab after initial treatment with ipilimumab and nivolumab works in treating patients with renal cell cancer that has spread to other parts of the body. This study has 2 arms: Arm A: Nivolumab INDUCTION: Patients receive nivolumab intravenously (IV) in clinic over 30 or 60 minutes PLUS ipilimumab IV over 60 minutes on day 1 of every 21 day cycle, for up to 4 cycles. TREATMENT: Patients receive nivolumab IV over 30 or 60 minutes on day 1 of every 28 day cycle. Arm B: Nivolumab + Cabozantinib INDUCTION: Patients receive nivolumab intravenously (IV) in clinic over 30 or 60 minutes PLUS ipilimumab IV over 60 minutes on day 1 of every 21 day cycle, for up to 4 cycles. TREATMENT: Patients receive nivolumab IV over 30 or 60 minutes on day 1 of every 28 day cycle PLUS cabozantinib orally (by mouth or PO) daily on days 1-28.

The purpose of this study is to evaluate the effectiveness and safety of belzutifan (Welireg, a type of targeted therapy) monotherapy and belzutifan plus palbociclib (Ibrance, a type of targeted therapy) combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by increasing the dose. Part 2 will evaluate the effectiveness and safety of belzutifan plus palbociclib at the dosage level determined in Part 1. This study has 2 main treatment arms: Arm A: Belzutifan alone Participants receive belzutifan 120 mg by mouth (orally, PO) once daily until progressive disease or discontinuation. Pills are 40 mg tablets (3 tablets = 120 mg). Arm B: Belzutifan + Palbociclib Participants receive belzutifan 120 mg by mouth once daily PLUS palbociclib by mouth once daily at varying dose levels (75 mg, 100 mg or 125 mg) for 21 days (followed by 7 days off for a 28 day cycle) until progressive disease or discontinuation.

This is a Phase I/II, open-label, multi-center study of axitinib (Inlyta, a type of targeted therapy) in combination with nivolumab (Opdivo, a type of immunotherapy) in patients with previously treated and untreated advanced renal cell carcinoma (RCC). This clinical study will be composed of a dose finding phase (Phase I) and two parallel dose expansion phases (Phase II). The dose finding phase will assess the safety of the combination and establish a recommended phase II dose in patients with advanced RCC who have received prior systemic therapy for metastatic disease. Phase II will evaluate the effectiveness of the combination in two parallel expansion cohorts in both previously treated and treatment naïve patients. All patients in all phases of this study will receive both drugs, at various doses. Axitinib is taken orally (by mouth) twice daily, although dose and dosing schedule may vary. Nivolumab is given intravenously (IV), dose and dosing schedule may vary.

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab (Opdivo), ipilimumab (Yervoy), pembrolizumab (Keytruda), and avelumab (Bavencio), may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib (Inlyta, a type of targeted therapy) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer. This study has 2 treatment arms: Arm A: Systemic Therapy Only Patients receive intravenous (IV) immunotherapy with one or two immunotherapy drugs with or without oral Axitinib. Dosing schedule and regimen will be provided by the treating physician. Arm B: Nephrectomy and Systemic Therapy Patients receive intravenous (IV) immunotherapy with one or two immunotherapy drugs with or without oral Axitinib. Dosing schedule and regimen will be provided by the treating physician. Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches.

This trial is a prospective, observational study is to understand the cancer management and health-related quality of life in patients with metastatic renal cell carcinoma (mRCC) in routine real-world clinical practice in the United States, including both community and academic treatment settings. Primarily, the study will evaluate patient experience through collection of patient reported outcomes (PROs). The study will also collect and assess information on the therapies used such as first-line treatment selection, treatment sequence and duration, the drivers of physician selection of particular agents, and discontinuation of therapies. The primary objective is to determine distinct patterns of change in the quality of life and symptom burden in mRCC patients receiving therapy. Patients will be identified and undergo consent and baseline assessments, including research blood collection and processing, by the study site team, this baseline visit will be their only clinic visits per protocol. All other visits are standard of care visits and outside the scope of the study.

Multicenter, open-label dose-escalation Phase I/II clinical study, designed to evaluate the safety, tolerability, activity, anti-tumor activity, and effectiveness of TT-10 (a type of targeted therapy) in subjects diagnosed with advanced Renal cell cancer (RCC) and castrate resistant prostate cancer (CRPC) who have failed or are not eligible for standard of care treatment. All patients will receive treatment with TT-10 orally administered (by mouth, po) twice daily starting at 10 mg and will be increased to 200 mg (additional dose levels maybe explored, if appropriate).

The purpose of this study is to test the safety of an investigational drug called CFI-402411 (a type of targeted therapy) alone and in combination with pembrolizumab (Keytruda, a type of immunotherapy) and to study its effects in patients with advanced solid tumors (including bladder and kidney cancer) who have progressed following previous therapies. This study has 2 treatment arms: Arm A: CFI-402411 alone CFI-402411 is administered orally (po or by mouth) once daily. The starting dose is 80 mg/day. Specific dose will be provided by your treating physician. Arm B: CFI-402411 + pembrolizumab CFI-402411 is administered orally (po or by mouth) once daily. The starting dose is 80 mg/day. Specific dose will be provided by your treating physician. Pembrolizumab will be given at, 200 mg administered as an intravenous (IV) infusion over 30 minutes every 3 weeks.

This is a single arm, single site, open-label Phase II study of the effects of oral olaparib (Lynparza, a type of targeted therapy, a PARP inhibitor) in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor (immunotherapy) or anti-VEGF therapy (targeted therapy). This study has 1 arm: Olaparib: Participants will be initially treated with olaparib 150 mg by mouth (PO) twice daily for one month. After one month of therapy, the dose will be increased to 300mg by mouth twice daily, if tolerated. Treatment will be continued until clinical and/or radiographic progression or unmanageable side effects requiring discontinuation of the drug.

This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety, tolerability, and effectiveness of XTX202, an engineered IL-2 prodrug (a type of immunotherapy) as monotherapy in patients with advanced solid tumors. All subjects will receive study drug, XTX202 at various dose levels. Dose levels and dosing schedule will be provided by the treatment team.

Genitourinary cancers are some of the most common types of cancer. They are lethal when they spread. The drug M7824 blocks the paths that cancer cells use to stop the immune system from fighting cancer. The drug M9241 triggers the immune system to fight cancer. Researchers want to learn if these drugs can help fight these cancers when given with and without Stereotactic Body Radiation Therapy (SBRT) radiation. This study has 3 treatment arms: Arm A: Treatment with M7824 and deescalating (decreasing) doses of M9241, if appropriate Drug: M7824 1200 mg administered intravenously (IV) in clinic every two weeks while on M9241 and with or without SBRT Drug: M9241 an initial dose of 16.8 mcg/kg administered subcutaneously (SC or SQ) every 4 weeks while on M7824 and with or without SBRT Arm B: Treatment with M7824 and deescalating doses of M9241 (if appropriate) with sequential SBRT Drug: M7824 1200 mg administered IV every two weeks while on M9241 and with or without SBRT Drug: M9241 an initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT Radiation: Stereotactic body radiation therapy (SBRT) a fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and M9241 Arm C: Treatment with M7824 and deescalating doses of M9241 (if appropriate) with concurrent SBRT Drug: M7824 1200 mg administered IV every two weeks while on M9241 and with or without SBRT Drug: M9241 an initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT Radiation: Stereotactic body radiation therapy (SBRT) a fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and M9241

This is a study of vobramitamab duocarmazine (MGC018, a type of targeted therapy) in combination with lorigerlimab (a type of immunotherapy). The study is designed to characterize safety, tolerability, drug activity, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including metastatic castration resistant prostate cancer (mCRPC) and renal cell carcinoma (RCC) will be enrolled. All participants will receive treatment. Vobramitamab duocarmazine and lorigerlimab will be given intravenously (IV) once every 4 weeks. Dosage level will be provided by the treatment team.

The purpose of this study is to assess the effectiveness and safety of oral belzutifan (MK-6482, Welireg, a type of targeted therapy) plus intravenous (IV) pembrolizumab (MK-3475, Keytruda, a type of immunotherapy) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS). This study has 2 treatment arms: Arm A: Belzutifan + Pembrolizumab Participants receive belzutifan 120 mg orally (by mouth, PO) once daily for up to approximately 54 weeks PLUS pembrolizumab 400 mg via intravenous (IV) infusion once every 6 weeks for up to 9 administrations (up to approximately 54 weeks). Arm B: Placebo + Pembrolizumab Participants receive placebo orally once daily for up to approximately 54 weeks PLUS pembrolizumab 400 mg via IV infusion once every 6 weeks for up to 9 administrations (up to approximately 54 weeks).

The trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory markers with the exercise intervention. This study does NOT include treatment. This is supportive Care for patients with metastatic renal cell carcinoma (mRCC) who are receiving immune-checkpoint inhibitor therapy (immunotherapy). Participants receive a personalized exercise plan for home-based, two days of aerobic exercises (20-30-minutes) and two days of resistance exercises per week for 12 weeks. After completion of study intervention, participants will be assessed at the of study visit at Week 24.

This phase II trial compares the effect of atezolizumab (Tecentriq, a type of immunotherapy) in combination with usual treatment with cabozantinib (Cabometyx, a type of targeted therapy) to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Immunotherapy, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is a type of targeted therapy that works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma. This study has 2 arms: Arm A: Cabozantinib alone Patients receive cabozantinib S-malate orally (by mouth or PO) once daily (QD) on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Arm B: Cabozantinib + Atezolizumab Patients receive cabozantinib S-malate PO QD on days 1-21 and atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

This is a Phase 1/2 open label multicenter study of NKT2152 (a type of targeted therapy). Phase 1 is a first in human (FIH) dose escalation study in patients aged 18 years or older with clear cell renal carcinoma (ccRCC) who have exhausted available standard therapy as determined by the investigator. Eligible patients will have received <=4 prior lines of therapy. The goal of the Phase 1 portion is to identify the maximum tolerated dose and/or the recommended Phase 2 Dose of NKT2152. The Phase 2 portion will evaluate the effectiveness of NKT2152 in ccRCC. All subjects will receive NKT2152 taken once daily by mouth (orally or PO). Dosage will be provided by treatment team.

Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist, a type of targeted therapy) in patients with renal cell carcinoma (RCC - clear cell and papillary), and urothelial tumors. This study includes single agent dose escalation and dose finding of PF 06940434 in combination with anti-PD-1 (a type of immunotherapy) and dose expansion. This study has 2 treatment arms: Arm A: Single agent PF-06940434 PF-06940434 is given intravenously (IV) every 2 weeks in a 28 day cycle. Multiple dose levels will be evaluated. Dosage will be provided by the treatment team. Arm B: PF-06940434 + anti-PD-1 PF-06940434 is given intravenously (IV) every 2 weeks in a 28 day cycle. Multiple dose levels will be evaluated. PLUS PF-06801591 (anti-PDL1) will be administered subcutaneously (sc or sq, an injection just under the skin) on Day 1 of each 28 day cycle. Dosages for both drugs will be provided by the treatment team.

This phase II trial studies the effects of combination therapy with bevacizumab (Avastin, a type of targeted therapy), erlotinib (Tarceva, a type of targeted therapy), and atezolizumab (Tecentriq, a type of immunotherapy) in treating patients with hereditary leiomyomatosis and kidney cancer that has spread to other places in the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer. This study has one treatment arm: Bevacizumab + Atezolizumab + Erlotinib Patients receive bevacizumab intravenously (IV) over 30-90 minutes and atezolizumab IV over 30-90 minutes on day 1 of each cycle. Patients also receive erlotinib by mouth (orally or PO) once daily on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed. Most patients with advanced clear cell RCC are treated with immunotherapy and targeted therapy. There are few options for patients who have progressed on these therapies. There is currently no widely accepted standard treatment for patients with papillary renal cell carcinoma, although some patients may benefit from targeted therapy. Preclinical data suggest that inhibitors of CDK 4/6 (targeted therapy) might be active in kidney cancer and that these agents might act synergistically with immunotherapy. The objective of this study is to the safety and effectiveness of combining palbociclib (a type of targeted therapy inhibiting CDK4/6) and sasanlimab (a type of immunotherapy). All participants receive treatment with palbociclib given by mouth (PO, orally) + sasanlimab given by subcutaneous injection (sc or sq). Dosage and dosing schedule will be provided by the treatment team.